These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 33714800

  • 1. Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits.
    Laserna-Mendieta EJ, Salvador-Martín S, Marín-Jiménez I, Menchén LA, López-Cauce B, López-Fernández LA, Lucendo AJ.
    J Pharm Biomed Anal; 2021 May 10; 198():114003. PubMed ID: 33714800
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
    Valor L, Hernández-Flórez D, de la Torre I, Llinares F, Rosas J, Yagüe J, Garrido J, Naredo E.
    Clin Exp Rheumatol; 2015 May 10; 33(5):617-23. PubMed ID: 26316061
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels.
    Novakovic V, Abdija S, Larsen PB, Fenger M, Gredal L, Jacobsen KK.
    Clin Biochem; 2019 Dec 10; 74():73-75. PubMed ID: 31669514
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits.
    Bertin D, Serrero M, Grimaud JC, Desjeux A, Desplat-Jégo S.
    Cytokine; 2020 Feb 10; 126():154859. PubMed ID: 31629989
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels.
    Ogrič M, Žigon P, Drobne D, Štabuc B, Sodin-Semrl S, Čučnik S, Praprotnik S.
    Immunol Res; 2018 Dec 10; 66(6):726-736. PubMed ID: 30569379
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of Infliximab and Anti-infliximab LISA-TRACKER Immunoassays for the Therapeutic Drug Monitoring of SB2 Infliximab Biosimilar.
    Jentzer A, Berger AE, Labetoulle R, Haccourt A, Roblin X, Paul S.
    Ther Drug Monit; 2018 Dec 10; 40(6):749-753. PubMed ID: 30439790
    [Abstract] [Full Text] [Related]

  • 19. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
    Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K, Steenholdt C.
    Inflamm Bowel Dis; 2014 Oct 10; 20(10):1714-21. PubMed ID: 25069030
    [Abstract] [Full Text] [Related]

  • 20. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
    Van Stappen T, Brouwers E, Tops S, Geukens N, Vermeire S, Declerck PJ, Gils A.
    Ther Drug Monit; 2015 Aug 10; 37(4):479-85. PubMed ID: 25525757
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.